PRGO

Perrigo Company plc

Fundamental data last updated:November 20, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - Specialty & Generic

Exchange

NYSE

County of HQ

IE

Next Earnings Date

02/25/2027

Business Summary

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

 


VALUATION

P/E

-1.27

Market Cap ($M USD)

$2.25B

Forward P/E

7.10

PEG

0.07

PRICE TO SALES

0.55

PRICE TO BOOK

0.93

EV / EBITDA

-4.77

5-Year Average P/E

Free Cash Flow Yield

9.93%

DCF Value

$53.74

Graham Number

N/A

Price to FCF

10.07

EV to FCF

23.54

Earnings Yield

-78.17%

FCF Yield

9.93%

DIVIDEND

Yield

7.14%

Annual Payout

$1.16

Payout Ratio

-11.31%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$12.70

Next Year EPS Growth Estimate

$2.29

Next Year Revenue Growth Estimate

$3.99B

Return on Equity (ROE)

-68.13%

FREE CASH FLOW

Operating Margin

4.05%

Debt-to-Equity

1.42

Piotroski F-Score

4

Altman Z-Score

-0.38

Return on Invested Capital (ROIC)

2.55%

Current Ratio

2.35

Quick Ratio

1.36

Net Debt to EBITDA

-2.73

Interest Coverage

1.13

Gross Profit margin

32.33%

FCF PER SHARE

$1.61

REVENUE PER SHARE

$29.34

Gainseekers Quantitative Analysis

Summary

Perrigo Company plc’s valuation presents a perplexing narrative. Despite a staggering DCF value, the stock has traded significantly below this intrinsic measure, suggesting a potential market mispricing. The Forward P/E of 4.04 implies optimism for future earnings, yet the negative Earnings Yield and Altman Z-score signal financial distress and potential insolvency risks. The market seems to be betting on a turnaround, but the negative Return on Equity and substantial debt levels raise red flags about management’s past execution and financial health.

AI Exposure / Tech Reliance

In the realm of AI and tech adaptation, Perrigo operates within the healthcare sector, specifically in drug manufacturing, which is traditionally slower to integrate cutting-edge tech. However, the industry's ongoing digital transformation, including AI-driven drug discovery and supply chain optimization, could offer Perrigo opportunities to enhance efficiency. Their ability to leverage these technologies will be crucial in maintaining competitiveness.

The Bull Case

For the value-driven investor, Perrigo offers intriguing prospects. The ROIC of 3.39% and a solid FCF Yield suggest efficient capital allocation, while a Piotroski F-Score of 4 indicates moderate financial health. With a Gross Profit Margin of 34.17%, the company demonstrates pricing power in its niche market. These metrics collectively paint a picture of a company with potential for operational improvement and value creation.

The Bear Case

Yet, the bear case is hard to ignore. The negative Price/Earnings ratio and a concerning Altman Z-score highlight significant financial instability. The company's high Debt/Equity ratio of 1.35 further exacerbates the risk, indicating potential liquidity issues. Trading far below its 52-week high, the stock's technical position reflects market skepticism about its recovery prospects.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$36.20

Institutional Ownership %

1-Year Beta

0.54

Insider Buying % (6 Mo)

Distance to 52-Week High

4.80%

Distance to 52-Week Low

43.17%

EARNINGS SURPRISE %

17.42%

50-DAY SMA

$15.17

200-DAY SMA

$12.52

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.